3646 results for «689»
3646 results
Various NSTEMI cases
21 May 2026 – From EuroPCR 2026
This session presents diverse NSTEMI case studies addressing complex diagnostic and interventional challenges, including coronary dissections, intramural hematomas, ischemic complications, and functional lesion assessment.
Risk stratification and reperfusion strategies for acute and subacute pulmonary embolism
21 May 2026 – From EuroPCR 2026
Focus on risk stratification and reperfusion strategies for acute and subacute pulmonary embolism through this session. It discusses the impact of elective endovascular therapies in intermediate-high risk patients, intraprocedural complications, and early mortality associated with catheter interventions. Additionally, it reviews real-world outcomes of catheter-directed therapy, national...
Percutaneous management of mitral and aortic valve disease
21 May 2026 – From EuroPCR 2026
Delve into the percutaneous management of mitral and aortic valve disease through detailed procedural demonstrations. This session covers valve-in-valve procedures, navigation of potential complications in valve-in-valve TAVI, and mitral valve edge-to-edge repair techniques, supported by real-world case discussions and key learnings.
Complex multivessel disease: from calcium to physiology - Case-based decisions
21 May 2026 – From EuroPCR 2026
Focus on complex multivessel coronary artery disease management with an emphasis on severely calcified lesions and the integration of intracoronary imaging and physiology. This session prepares clinicians to anticipate and manage complications during PCI, enhancing competence in treating challenging coronary anatomies through case-based decision-making.
Performing BASILICA: a step-by-step guide to prevent coronary obstruction during TAVI
05 Aug 2025
Author
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
